BACKGROUND AND OBJECTIVE:Veliparib (ABT-888) is a potent oral inhibitor of Poly(ADP-ribose) polymerase enzyme that is currently in development for the treatment of non-hematologic and hematologic malignancies. This analysis characterizes the population pharmacokinetics of veliparib, including developing a structural pharmacokinetic model and testing patient demographics and covariates for potential influence on veliparib pharmacokinetics in patients with non-hematologic malignancies. METHODS: The analysis dataset included 3,542 veliparib concentration values from 325 patients with non-hematologic malignancies enrolled in three phase I and one phase II studies. Population pharmacokinetic modeling was performed using NONMEM. The likelihood ratio test was used for comparison of nested models, and visual predictive check was employed for model qualification. Covariates tested included body size measures, creatinine clearance (CLCR), formulation, age, sex, race, liver function tests, and coadministration with temozolomide. RESULTS: A one-compartment model with first-order absorption and elimination adequately described veliparib pharmacokinetics. The final model included fixed effects for CLCR on veliparib oral clearance (CL/F) and lean body mass (LBM) on volume of distribution (V d/F). CL/F and V d/F were 20.9 L/h (for a CLCR of 100 mL/min) and 173 L (for an LBM of 56 kg), respectively. CONCLUSION: Only LBM and CLCR were found to be determinants of veliparib V d/F and CL/F, respectively. Dosage adjustments of veliparib on the basis of body size, age, sex, race, liver function, and temozolomide coadministration are not necessary in patients with non-hematologic malignancies. This is the first study to characterize the population pharmacokinetics of veliparib, and the developed model will be used to conduct simulations and evaluate veliparib exposure-response relationships.
RCT Entities:
BACKGROUND AND OBJECTIVE:Veliparib (ABT-888) is a potent oral inhibitor of Poly(ADP-ribose) polymerase enzyme that is currently in development for the treatment of non-hematologic and hematologic malignancies. This analysis characterizes the population pharmacokinetics of veliparib, including developing a structural pharmacokinetic model and testing patient demographics and covariates for potential influence on veliparib pharmacokinetics in patients with non-hematologic malignancies. METHODS: The analysis dataset included 3,542 veliparib concentration values from 325 patients with non-hematologic malignancies enrolled in three phase I and one phase II studies. Population pharmacokinetic modeling was performed using NONMEM. The likelihood ratio test was used for comparison of nested models, and visual predictive check was employed for model qualification. Covariates tested included body size measures, creatinine clearance (CLCR), formulation, age, sex, race, liver function tests, and coadministration with temozolomide. RESULTS: A one-compartment model with first-order absorption and elimination adequately described veliparib pharmacokinetics. The final model included fixed effects for CLCR on veliparib oral clearance (CL/F) and lean body mass (LBM) on volume of distribution (V d/F). CL/F and V d/F were 20.9 L/h (for a CLCR of 100 mL/min) and 173 L (for an LBM of 56 kg), respectively. CONCLUSION: Only LBM and CLCR were found to be determinants of veliparib V d/F and CL/F, respectively. Dosage adjustments of veliparib on the basis of body size, age, sex, race, liver function, and temozolomide coadministration are not necessary in patients with non-hematologic malignancies. This is the first study to characterize the population pharmacokinetics of veliparib, and the developed model will be used to conduct simulations and evaluate veliparib exposure-response relationships.
Authors: Sarayut Janmahasatian; Stephen B Duffull; Susan Ash; Leigh C Ward; Nuala M Byrne; Bruce Green Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447
Authors: Stephen B Duffull; Michael J Dooley; Bruce Green; Susan G Poole; Carl M J Kirkpatrick Journal: Clin Pharmacokinet Date: 2004 Impact factor: 6.447
Authors: Corine Ekhart; Sjoerd Rodenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema Journal: Cancer Chemother Pharmacol Date: 2008-11-07 Impact factor: 3.333
Authors: Ronald Stoller; John C Schmitz; Fei Ding; Shannon Puhalla; Chandra P Belani; Leonard Appleman; Yan Lin; Yixing Jiang; Salah Almokadem; Daniel Petro; Julianne Holleran; Brian F Kiesel; R Ken Czambel; Benedito A Carneiro; Emmanuel Kontopodis; Pamela A Hershberger; Madani Rachid; Alice Chen; Edward Chu; Jan H Beumer Journal: Cancer Chemother Pharmacol Date: 2017-08-02 Impact factor: 3.333
Authors: Jacob D Soumerai; Andrew D Zelenetz; Craig H Moskowitz; M Lia Palomba; Paul A Hamlin; Ariela Noy; David J Straus; Alison J Moskowitz; Anas Younes; Matthew J Matasar; Steven M Horwitz; Carol S Portlock; Jason A Konner; Mrinal M Gounder; David M Hyman; Martin H Voss; Matthew G Fury; Devika Gajria; Richard D Carvajal; Alan L Ho; Jan H Beumer; Brian Kiesel; Zhigang Zhang; Alice Chen; Richard F Little; Christine Jarjies; Thu O Dang; Fallon France; Nishant Mishra; John F Gerecitano Journal: Clin Cancer Res Date: 2017-03-17 Impact factor: 12.531
Authors: Patricia A Baxter; Jack M Su; Arzu Onar-Thomas; Catherine A Billups; Xiao-Nan Li; Tina Young Poussaint; Edward R Smith; Patrick Thompson; Adekunle Adesina; Pete Ansell; Vincent Giranda; Arnold Paulino; Lindsey Kilburn; Ibrahim Quaddoumi; Alberto Broniscer; Susan M Blaney; Ira J Dunkel; Maryam Fouladi Journal: Neuro Oncol Date: 2020-06-09 Impact factor: 12.300
Authors: Keith W Pratz; Michelle A Rudek; Ivana Gojo; Mark R Litzow; Michael A McDevitt; Jiuping Ji; Larry M Karnitz; James G Herman; Robert J Kinders; B Douglas Smith; Steven D Gore; Hetty E Carraway; Margaret M Showel; Douglas E Gladstone; Mark J Levis; Hua-Ling Tsai; Gary Rosner; Alice Chen; Scott H Kaufmann; Judith E Karp Journal: Clin Cancer Res Date: 2016-08-22 Impact factor: 12.531
Authors: Leonard J Appleman; Jan H Beumer; Yixing Jiang; Yan Lin; Fei Ding; Shannon Puhalla; Leigh Swartz; Taofeek K Owonikoko; R Donald Harvey; Ronald Stoller; Daniel P Petro; Hussein A Tawbi; Athanassios Argiris; Sandra Strychor; Marie Pouquet; Brian Kiesel; Alice P Chen; David Gandara; Chandra P Belani; Edward Chu; Suresh S Ramalingam Journal: Cancer Chemother Pharmacol Date: 2019-09-23 Impact factor: 3.333
Authors: Renu Singh; Shailly Mehrotra; Mathangi Gopalakrishnan; Ivana Gojo; Judith E Karp; Jacqueline M Greer; Alice Chen; Richard Piekarz; Brian F Kiesel; Jogarao Gobburu; Michelle A Rudek; Jan H Beumer Journal: Cancer Chemother Pharmacol Date: 2018-11-20 Impact factor: 3.333
Authors: Ivana Gojo; Jan H Beumer; Keith W Pratz; Michael A McDevitt; Maria R Baer; Amanda L Blackford; B Douglas Smith; Steven D Gore; Hetty E Carraway; Margaret M Showel; Mark J Levis; Amy E Dezern; Douglas E Gladstone; Jiuping Jay Ji; Lihua Wang; Robert J Kinders; Marie Pouquet; Ismail Ali-Walbi; Michelle A Rudek; Weijie Poh; James G Herman; Larry M Karnitz; Scott H Kaufmann; Alice Chen; Judith E Karp Journal: Clin Cancer Res Date: 2016-08-08 Impact factor: 12.531